William Hinton

List of Publications by Year
in descending order

35 papers	805 citations	686830 13 h-index	525886 27 g-index
38 all docs	38 docs citations	38 times ranked	1199 citing authors

#	Article	IF	Citations
1	Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open, 2016, 6, e011092.	0.8	167
2	Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 2018, 20, 1040-1043.	2.2	101
3	Incidence and prevalence of cardiovascular disease in English primary care: a cross-sectional and follow-up study of the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). BMJ Open, 2018, 8, e020282.	0.8	83
4	Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis. PLoS Medicine, 2019, 16, e1002942.	3.9	65
5	Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. BMJ Open, 2016, 6, e012801.	0.8	44
6	Association Between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45‰418 Symptomatic Patients With Hypertension. Hypertension, 2021, 77, 846-855.	1.3	41
7	A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study. Diabetes Therapy, 2018, 9, 229-242.	1.2	28
8	A wake-up call for preconception health: a clinical review. British Journal of General Practice, 2021, 71, 233-236.	0.7	27
9	The association between diabetes, level of glycaemic control and eye infection: Cohort database study. Primary Care Diabetes, 2017, 11, 421-429.	0.9	24
10	Trends in diabetes medication use in Australia, Canada, England, and Scotland: a repeated cross-sectional analysis in primary care. British Journal of General Practice, 2021, 71, e209-e218.	0.7	24
11	Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol. BMJ Open, 2016, 6, e010469.	0.8	22
12	Glycemic control is an important modifiable risk factor for uveitis in patients with diabetes: A retrospective cohort study establishing clinical risk and ophthalmic disease burden. Journal of Diabetes and Its Complications, 2018, 32, 602-608.	1.2	18
13	Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. Diabetes, Obesity and Metabolism, 2019, 21, 1661-1667.	2.2	18
14	Trends in end digit preference for blood pressure and associations with cardiovascular outcomes in Canadian and UK primary care: a retrospective observational study. BMJ Open, 2019, 9, e024970.	0.8	17
15	U-shaped relationship between serum phosphate and cardiovascular risk: A retrospective cohort study. PLoS ONE, 2017, 12, e0184774.	1.1	13
16	The association between serum sodium concentration, hypertension and primary cardiovascular events: a retrospective cohort study. Journal of Human Hypertension, 2019, 33, 69-77.	1.0	12
17	Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality. Atherosclerosis, 2021, , .	0.4	10
18	Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 1310-1318.	2.2	10

#	Article	IF	Citations
19	Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study. Family Practice, 2022, 39, 1049-1055.	0.8	10
20	Diabetic retinopathy in newly diagnosed Type 2 diabetes mellitus: Prevalence and predictors of progression; a national primary network study. Diabetes Research and Clinical Practice, 2021, 175, 108776.	1.1	9
21	Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism. Diabetic Medicine, 2021, 38, e14452.	1.2	8
22	Trends in Factors Affecting Pregnancy Outcomes Among Women With Type 1 or Type 2 Diabetes of Childbearing Age (2004â€"2017). Frontiers in Endocrinology, 2020, 11, 596633.	1.5	8
23	Common Data Models (CDMs) to Enhance International Big Data Analytics: A Diabetes Use Case to Compare Three CDMs. Studies in Health Technology and Informatics, 2018, 255, 60-64.	0.2	7
24	Association Between Diabetes, Level of Glycemic Control, and Eye Infection: A Cohort Study. Diabetes Care, 2017, 40, e30-e31.	4.3	6
25	Overâ€use of thyroid testing in Canadian and UK primary care in frequent attenders: A crossâ€sectional study. International Journal of Clinical Practice, 2021, 75, e14144.	0.8	6
26	Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis. Cardiovascular Diabetology, 2021, 20, 130.	2.7	6
27	Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol). BMC Health Services Research, 2019, 19, 284.	0.9	5
28	Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice. BMC Medical Research Methodology, 2020, 20, 198.	1.4	5
29	Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol. Diabetes Therapy, 2018, 9, 1397-1402.	1.2	3
30	How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol. Diabetes Therapy, 2019, 10, 1163-1170.	1.2	3
31	Dashboards to reduce inappropriate prescribing of metformin and aspirin: A quality assurance programme in a primary care sentinel network. Primary Care Diabetes, 2021, 15, 1075-1079.	0.9	2
32	Commentary: A lack of a comparator group makes it hard to be sure whether computerised medical record system implementation achieved a better or worse outcome. Journal of Innovation in Health Informatics, 2016, 23, 485.	0.9	1
33	Does Renal Function or Heart Failure Diagnosis Affect Primary Care Prescribing for Sodium-Glucose Co-TransporterÂ2 Inhibitors in TypeÂ2 Diabetes?. Diabetes Therapy, 2020, 11, 2169-2175.	1.2	1
34	Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study). JMIR Research Protocols, 2022, 11, e34206.	0.5	0
35	The Effect of the COVID-19 Pandemic on Glycemic Monitoring and Other Processes of Care for Type 2 Diabetes: Protocol for a Retrospective Cohort Study. JMIR Research Protocols, 2022, 11, e35971.	0.5	0